GeneDx has unveiled an ultrarapid whole genome sequencing service delivering diagnostic results for critically ill neonatal and paediatric patients within 48 hours. This technological advancement could potentially generate healthcare savings exceeding $15,000 per child while significantly enhancing clinical outcomes through earlier intervention.
Testa Analytical has released a differential refractometer that promises to significantly improve the accuracy of molecular weight determination in biopolymers and polymers. The instrument, designed specifically as an accessory for light scattering equipment, addresses one of the fundamental challenges in molecular characterisation: obtaining precise specific refractive index increment (dn/dc) values.
MIMETAS has introduced OrganoPlate UniFlow (UF), the first commercial platform offering unidirectional, gravity-driven pumpless flow systems for disease research. This innovation significantly advances tissue model development for pharmaceutical research by replicating physiological conditions without complex equipment.
CN Bio has launched an all-in-one drug-induced liver injury (DILI) testing kit that enables pharmaceutical researchers to conduct in-house hepatotoxicity screening using organ-on-chip technology. The system provides human-relevant data to support more informed candidate selection during preclinical development.
Cambridge scientists at EDX Medical Group have developed an innovative diagnostic test for prostate cancer that combines over 100 biomarkers with AI analysis, potentially transforming screening accuracy with sensitivity and specificity rates between 96-99%.
Discover the perfect solution for every laboratory size. Due to its compact design respons®240c is ideal for small labs that require an analyzer capable of a constant throughput of 240 tests/hour along with intuitively operated software. Advanced features like onboard hemolysis and a grated photometer with 12 wavelengths ensure precision and efficiency.
A new sterile bead-based plating method offers enhanced efficiency and safety for microbiological work, potentially improving laboratory throughput and reproducibility.
Cambridge-based organ-on-chip technology company CN Bio has introduced a new in vitro assay kit designed to assess human oral drug bioavailability. The PhysioMimix Bioavailability assay kit: Human 18 enables pharmaceutical researchers to generate predictive human data earlier in the drug development pipeline, reducing reliance on animal studies.
Cambridge-based Enhanc3D Genomics has unveiled an integrated suite of multi-omics solutions designed to enhance drug discovery processes. The platform, which leverages proprietary Promoter Capture Hi-C technology, enables high-resolution mapping of genomewide regulatory interactions to support more targeted therapeutic development approaches.
Revvity Inc has announced FDA 510(k) clearance for EUROIMMUN’s automated chemilumin-escence immunoassay (ChLIA) for direct quantitative measurement of free testosterone. The assay, which runs on the company’s iSYS and i10 platforms, represents the first FDA-cleared automated direct measurement method for free testosterone in human serum or plasma.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.